BUILD VS BUY: THE PRACTICALITIES, IMPLICATIONS, AND ECONOMICS OF MANUFACTURING GENE THERAPIES
Time: 9:00 am
day: Workshop Day - track a
Details:
- Assessing the CDMO field in 2024: is there sufficient expertise, capacity, and available skilled workers to meet gene therapy demand?
- How to choose to develop in-house or outsource?
- Developing a framework for small to midsize biopharma companies to weigh up the pros and cons of both routes
- Financial implications for both routes, and practical advice for mitigating unsustainable manufacturing costs
- When progressing successfully through the clinical, what are the key considerations for switching smoothly from ‘buy’ to ‘build’?
Speakers:
